...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Marching on to March events
Reply New Message
Back To Forum List View
Icon president Marching on to March events
1
BearDownAZ
Feb 14, 2018 05:50PM
Re: Marching on to March events

Hartland
Feb 15, 2018 03:17PM
Icon president Re: Marching on to March events
5
BearDownAZ
Feb 15, 2018 04:30PM

Also, in an update that Tada shared with us that was dated January 22, 2018 for the enzalutamide/ZEN-3694 combo trial:

"The patients in the second cohort are now up to 43 weeks. The maximum tolerated dose for the single agent trial of 60mgs has now been exceeded in the combination trial."

So if that second cohort is still going, add a few weeks to that and we're now at ~46 weeks. 

5 Recommendations
Re: Marching on to March events

Hartland
Feb 15, 2018 09:15PM
Icon president Re: Marching on to March events
4
BearDownAZ
Mar 12, 2018 12:15PM
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply